Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Trial Profile

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Infinity Pharmaceuticals; Verastem Oncology
  • Most Recent Events

    • 07 Mar 2019 Results (n=31) assessing clinical activity in indolent non-hodgkin's lymphoma patients, published in the Verastem Oncology Media Release.
    • 07 Mar 2019 According to a Verastem Oncology Media Release, data from this study and NCT01882803, NCT02004522,NCT02049515 was presented at the 23rd Annual International Congress on Hematologic Malignancies (ICHM), which took place February 28 to March 3, 2019, in Miami, Florida.
    • 04 Dec 2018 Results of pooled analysis evaluating efficacy and safety analysis from [NCT01476657],[NCT01882803],[NCT02004522],[NCT02049515) studies in RR CLL/SLL, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top